PLoS One [2013] 8 (7) : e69738 (C.Q.Zhou, S.S.Li, Z.M.Chen, F.Q.Li, P.Lei, G.G.Peng)
A systematic review has been carried out on the clinical trials of rotigotine transdermal patch, in order to evaluate the efficacy, tolerability, and safety in Parkinson's Disease. Rotigotine transdermal patch is marketed as Neupro. Neupro is a transdermal system that provides continuous delivery of rotigotine, which is a dopamine agonist, for 24 hours following application to intact skin.
The use of rotigotine resulted in greater improvements in Parkinson's Disease symptom scores (the UPDRS) concerning the activities of daily living score, motor score, and the activities of daily living and motor subtotal score. However, rotigotine was associated with a significantly higher rate of withdrawals due to adverse events, and higher rates of application site reactions, vomiting, and dyskinesia. No differences were found in the relative risks of headache, constipation, back pain, diarrhea, or serious adverse events.
A systematic review has been carried out on the clinical trials of rotigotine transdermal patch, in order to evaluate the efficacy, tolerability, and safety in Parkinson's Disease. Rotigotine transdermal patch is marketed as Neupro. Neupro is a transdermal system that provides continuous delivery of rotigotine, which is a dopamine agonist, for 24 hours following application to intact skin.
The use of rotigotine resulted in greater improvements in Parkinson's Disease symptom scores (the UPDRS) concerning the activities of daily living score, motor score, and the activities of daily living and motor subtotal score. However, rotigotine was associated with a significantly higher rate of withdrawals due to adverse events, and higher rates of application site reactions, vomiting, and dyskinesia. No differences were found in the relative risks of headache, constipation, back pain, diarrhea, or serious adverse events. 
No comments:
Post a Comment